TP53 and myelodysplastic syndrome: Recent studies have shown that post-transplant survival in TP53-mutated MDS/AML is highly dependent on patient fitness and disease status, with poor outcomes in those with high comorbidity, poor performance, or residual disease at transplant (31, 32).